| Regression to normoglycaemia by fenofibrate in pre-diabetic subjects complicated with hypertriglyceridaemia: a prospective randomized controlled trial. | |
| | |
MedLine Citation:
|
PMID: 20968112 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
AIMS: Lipotoxicity has recently been shown to be an important risk factor underlying the pathogenesis of pre-diabetes. However, clinical evidence supporting the treatment of pre-diabetes by improving lipotoxicity is lacking. Here, we conducted an open-label, randomized, controlled trial to investigate whether fenofibrate, the widely used hypolipidaemic agent, might benefit pre-diabetes, with metformin and diet control, the recommended intervention methods, as positive controls. METHODS: Newly diagnosed pre-diabetes patients (n = 120) with hypertriglyceridaemia (plasma triglyceride levels between 1.8 and 4.5 mmol/l) were randomly assigned by computer-generated randomization sequence to either control group (no intervention), fenofibrate group (200 mg once a day), metformin group (500 mg three times a day) or diet-controlled group (diet recommendation). Plasma biochemistry examination was performed every 2 months. The primary endpoint was the outcome of the natural course of pre-diabetes, evaluated by oral glucose tolerance test after 6-month follow-up. RESULTS: Twenty subjects in the fenofibrate group, 24 subjects in the metformin group and 25 subjects in both the diet-controlled group and the control group finished the trial. Fenofibrate, metformin and diet control had protective effects on hypertriglyceridaemic pre-diabetes, evidenced by 53.3, 70 and 30% participants regressed to normoglycaemia, respectively. The effects of fenofibrate and metformin were comparable (P > 0.05), while diet control was less effective (P < 0.05). Liver damage occurred in six subjects in the fenofibrate group and gastrointestinal symptoms occurred in four subjects in the metformin group. No serious adverse events occurred. CONCLUSION: Controlling lipotoxicity by fenofibrate could effectively ameliorate the natural course of hypertriglyceridaemic pre-diabetes. |
| | |
Authors:
|
Q Wan; F Wang; F Wang; Q Guan; Y Liu; C Wang; L Feng; G Gao; L Gao; J Zhao |
Publication Detail:
|
Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Diabetic medicine : a journal of the British Diabetic Association Volume: 27 ISSN: 1464-5491 ISO Abbreviation: Diabet. Med. Publication Date: 2010 Nov |
Date Detail:
|
Created Date: 2010-10-22 Completed Date: 2011-01-07 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8500858 Medline TA: Diabet Med Country: England |
Other Details:
|
Languages: eng Pagination: 1312-7 Citation Subset: IM |
Affiliation:
|
Department of Endocrinology, Shandong Provincial Hospital/Shandong University. Institute of Endocrinology and Metabolic Diseases, Shandong Academy of Clinical Medicine, 324 Jingwu Road, Shandong, China. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Aged Blood Glucose* Female Fenofibrate / therapeutic use* Humans Hypertriglyceridemia / drug therapy* Hypoglycemic Agents / therapeutic use Hypolipidemic Agents / therapeutic use* Male Metformin / therapeutic use Middle Aged Prediabetic State / complications, drug therapy* Young Adult |
| Chemical | |
Reg. No./Substance:
|
0/Blood Glucose; 0/Hypoglycemic Agents; 0/Hypolipidemic Agents; 49562-28-9/Fenofibrate; 657-24-9/Metformin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: High prevalence of diabetes mellitus in patients with liver cirrhosis.
Next Document: High-cocoa polyphenol-rich chocolate improves HDL cholesterol in Type 2 diabetes patients.